Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Medicaid Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • High Postcancer Medical Bills
  • Federal Workers’ Health Data
  • Cyberattacks on Hospitals
  • ‘Cheap’ Insurance

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Apr 11 2019

Full Issue

Advocates Frustrated CDC Is Squandering Opportunity To Collect Royalties On HIV Prevention Drug

Negotiations with Gilead over royalties for the drug -- the research and development of which was funded by taxpayers -- are stalled. Advocates blast the CDC's inaction because they see that money as potentially going toward efforts to eradicate HIV. In other news from the Trump administration: a deadly drug-resistant fungus and an interview with the nation's top infectious disease doctor.

Stat: AIDS Activists Skewer CDC For Stance On Reaping HIV Drug Royalties 

Amid ongoing efforts to thwart HIV, AIDS activists are growing increasingly frustrated with the Centers for Disease Control and Prevention for failing to reach a deal with Gilead Sciences (GILD) over royalties on its sales of the Truvada prevention pill. Although the agency has refused to publicly discuss the subject, the activists hope any funds that could become available will be used for combating the virus. (Silverman, 4/10)

The Hill: CDC Says Nearly 600 Cases Of Deadly Drug-Resistant Fungus Reported 

The Centers for Disease Control and Prevention (CDC) has confirmed hundreds of cases of a deadly multidrug-resistant fungus nationwide. The CDC has confirmed 587 cases of the fungus, Candida auris, in 12 states over the past few years, most of them in Chicago, New Jersey and the New York City area. The fungus is a yeast infection with a one-in-three mortality rate in cases where the infection reaches the heart, blood or brain, according to the CDC. (Budryk, 4/10)

Politico's Pulse Check: Tony Fauci, The Nation's Top Infectious Disease Doctor

Tony Fauci joined NIH in 1968. He was named head of the National Institute of Allergy and Infectious Diseases in 1984. And on a warm day in April 2019, he sat down with POLITICO's Dan Diamond to reflect on his ongoing work — from the emergence of HIV/AIDS nearly 40 years ago to how the Trump administration is trying to end the epidemic. On the podcast, Fauci also discussed the resurgence of measles and other vaccine-preventable diseases, his perspective on the Trump administration and what it's like to give advice to a president. (4/11)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 22
  • Tuesday, April 21
  • Monday, April 20
  • Friday, April 17
  • Thursday, April 16
  • Wednesday, April 15
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF